» Articles » PMID: 21232712

Left Ventricular Remodeling in Heart Failure: Current Concepts in Clinical Significance and Assessment

Overview
Publisher Elsevier
Date 2011 Jan 15
PMID 21232712
Citations 316
Authors
Affiliations
Soon will be listed here.
Abstract

Ventricular remodeling, first described in animal models of left ventricular (LV) stress and injury, occurs progressively in untreated patients after large myocardial infarction and in those with dilated forms of cardiomyopathy. The gross pathologic changes of increased LV volume and perturbation in the normal elliptical LV chamber configuration is driven, on a histologic level, by myocyte hypertrophy and apoptosis and by increased interstitial collagen. Each of the techniques used for tracking this process-echocardiography, radionuclide ventriculography, and cardiac magnetic resonance-carries advantages and disadvantages. Numerous investigations have demonstrated the value of LV volume measurement at a single time-point and over time in predicting clinical outcomes in patients with heart failure and in those after myocardial infarction. The structural pattern of LV remodeling and evidence of scarring on cardiac magnetic resonance have additional prognostic value. Beyond the impact of abnormal cardiac structure on cardiovascular events, the relationship between LV remodeling and clinical outcomes is likely linked through common local and systemic factors driving vascular as well as myocardial pathology. As demonstrated by a recent meta-analysis of heart failure trials, LV volume stands out among surrogate markers as strongly correlating with the impact of a particular drug or device therapy on patient survival. These findings substantiate the importance of ventricular remodeling as central in the pathophysiology of advancing heart failure and support the role of measures of LV remodeling in the clinical investigation of novel heart failure treatments.

Citing Articles

Exercise in Diabetic Cardiomyopathy: Its Protective Effects and Molecular Mechanism.

Chen H, Guo L Int J Mol Sci. 2025; 26(4).

PMID: 40003929 PMC: 11855851. DOI: 10.3390/ijms26041465.


Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias: A Meta-Analysis of 38 Randomized Controlled Trials.

Jaiswal V, Ang S, Kumar D, Deb N, Jaiswal A, Joshi A JACC Adv. 2025; 4(3):101615.

PMID: 39985887 PMC: 11904486. DOI: 10.1016/j.jacadv.2025.101615.


Differentiating Apical and Basal Left Ventricular Aneurysms Using Sphericity Index: A Clinical Study.

Tomic S, Veljkovic S, Sljivo A, Radoicic D, Loncar G, Bojic M Medicina (Kaunas). 2025; 61(1).

PMID: 39859050 PMC: 11766783. DOI: 10.3390/medicina61010068.


Combination of C-reactive protein and fibrinogen-to-albumin ratio as a novel predictor of all-cause mortality in heart failure patients.

Yang S, Cai H, Hu Z, Huang W, Fu Q, Xia P Open Med (Wars). 2024; 19(1):20241045.

PMID: 39588387 PMC: 11587920. DOI: 10.1515/med-2024-1045.


Long-term surrogate cardiovascular outcomes of SGLT2 inhibitor empagliflozin in chronic heart failure: a systematic review and meta-analysis.

Yan Q, Chen X, Yu C, Yin Y BMC Cardiovasc Disord. 2024; 24(1):663.

PMID: 39578752 PMC: 11583546. DOI: 10.1186/s12872-024-04316-w.